NASDAQ · SXTC

China SXT Pharmaceuticals, Inc.

$0.07 +$0.01 (+9.40%) 1D Pre-market
Session Pulse Pre-market 1 mentions on Fri No new SEC filings since Mon close Full pulse →

Key Metrics

$2.44M
Market cap
P/E · TTM
Revenue · TTM
−$6.21M
Net income
EPS · TTM $-8,582.41
Dividend yield
Free cash flow −$4.02M
Beta · 1Y 1.30
EBITDA · TTM −$6.13M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    Offering paper hit the record (Form 424B5).

    424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

    RECEIPT: SEC FORM 424B5, TIMESTAMPED
  • Jul 24
    From its Feb 2 high, the share price fell 99%.

    Peak close $6.47 on Feb 2; trough close $0.06 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -99%
  • Jul 24
    The stock moved -80.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 24
  • Jul 23
    The stock moved -83.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 23
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.44M
Enterprise value−$25.08M
Shares outstanding38.2M
52-wk range$0.05 – $1,046.99
Avg volume · 20D788.3K
Net cash $27.52M
Book value / share$41,089.10
ExchangeNASDAQ
About China SXT Pharmaceuticals, Inc.
IPO dateJan 4, 2019
Employees56

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly TCMP (Directed-oral TCMP and After-soaking TCMP), which is a sort of Traditional Chinese Medicine (TCM…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -27.5% · —

Financial Health

Current ratio7.93
Quick ratio7.76
Debt / equity0.02
Debt / EBITDA -0.11
Net cash $27.52M
Working capital$30.16M

Cash Flow · TTM

Operating CF −$4.02M
Capex −$7.06K
Free cash flow −$4.02M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings